Medicine

Lessons from a negative gene treatment trial for Duchenne muscle dystrophy

.Attributes Medication, Posted online: 09 October 2024 doi:10.1038/ s41591-024-03316-9Delandistrogene moxeparvovec received FDA approval after a bad test, which highlights the various intricacies as well as difficulties of medication growth within this setting.